APO-APREMILAST 30 MG — DIN 02538180
APREMILAST : 30 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-APREMILAST?
APO-APREMILAST 30 MG contains APREMILAST : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02538180, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Sep-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-APREMILAST used for?
APO-APREMILAST is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. APO-APREMILAST, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response, intolerance, or contraindication to a prior disease-modifying anti-rheumatic drug (DMARD). APO-APREMILAST is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease who are candidates for systemic therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Apremilast cost around the world?
Apremilast is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 18 | 18 | EUR███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 8 | 18 | SEK███.██ |
| Slovakia | categorised final price | 13 | 14 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 12 | EUR███.██ |
| Saudi Arabia | public | 9 | 9 | SAR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 6 | CZK███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 4 | NOK███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
113 pack listings across 90 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Apremilast pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Apremilast in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Apremilast, across 22 DINs, of which 11 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 3 | 2 | AURO-APREMILAST | Sourceable in Canada |
| AMGEN CANADA INC | 2 | 2 | OTEZLA | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP APREMILAST | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 2 | SANDOZ APREMILAST | Sourceable in Canada |
| APOTEX INC | 4 | 1 | APO-APREMILAST, APO-APREMILAST TABLETS | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 2 | 1 | GLN-APREMILAST | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 1 | PMS-APREMILAST | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 2 | 0 | MAR-APREMILAST | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | TEVA-APREMILAST | No marketed DIN |
| MINT PHARMACEUTICALS INC | 1 | 0 | MINT-APREMILAST | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Apremilast |
|---|---|
| ATC code | L04AA32 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02538180 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2538180 |
| Brand name | APO-APREMILAST |
| Generic / active ingredient | APREMILAST : 30 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | L04AA32 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AA |
| Current status | MARKETED |
| Status date | 28-Sep-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
11 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-APREMILAST | 30 MG | TABLET | AURO PHARMA INC | MARKETED | 02524104 |
| AURO-APREMILAST | 10 MG | TABLET | AURO PHARMA INC | MARKETED | 02524120 |
| GLN-APREMILAST | 30 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02518910 |
| JAMP APREMILAST | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02528959 |
| JAMP APREMILAST | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02528967 |
| OTEZLA | 10 MG | TABLET | AMGEN CANADA INC | MARKETED | 02434318 |
| OTEZLA | 30 MG | TABLET | AMGEN CANADA INC | MARKETED | 02434334 |
| PMS-APREMILAST | 30 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02521733 |
| SANDOZ APREMILAST | 30 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02529084 |
| SANDOZ APREMILAST | 20 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02529092 |
2 · Same class — other molecules in ATC L04AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mycophenolic Acid | ACCEL-MYCOPHENOLATE MOFETIL CAPSULES · ACCEL-MYCOPHENOLATE MOFETIL TABLETS · ACH-MYCOPHENOLATE · AG-MYCOPHENOLATE · +21 more | 41 | 24 | Yes |
| Apremilast | APO-APREMILAST · APO-APREMILAST TABLETS · AURO-APREMILAST · GLN-APREMILAST · +7 more | 22 | 11 | Yes |
| Abatacept | ORENCIA | 3 | 2 | Yes |
| Antilymphocyte Immunoglobulin (Horse) | ATGAM · ATGAM STERILE SOLUTION IV 50MG/ML | 2 | 1 | Yes |
| Cladribine | MAVENCLAD | 1 | 1 | Yes |
| Efgartigimod Alfa | VYVGART | 1 | 1 | Yes |
| Belumosudil | REZUROCK | 1 | 1 | Yes |
| Antithymocyte Immunoglobulin (Rabbit) | THYMOGLOBULIN | 1 | 1 | Yes |
| Alefacept | AMEVIVE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-APREMILAST called?
The same molecule, Apremilast, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Otezla | Latin | Australia, Czechia, Iceland, Norway, Romania, Sweden |
| Apremilast Accord | Latin | Czechia, Norway, Sweden |
| Apremilast Teva | Latin | Czechia, Sweden |
| Apremilast Avansor | Latin | Sweden |
| Apremilast Krka | Latin | Sweden |
| Apremilast STADA | Latin | Sweden |
| Apremilast Zentiva | Latin | Sweden |
| Apriva | Latin | Bahrain, Saudi Arabia |
| Apremilast Hexal | Latin | Sweden |
| APRIVA (STARTER PACK) | Latin | Bahrain |
| Aprizla | Latin | Saudi Arabia |
| Milorizast | Latin | Saudi Arabia |
| Wetzo | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.